Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Grapefruit Benefits

Nevada Assembly Passes Bill To Protect Physicians On J-1 Visas
The Nevada Assembly last week voted to approve a bill (SB 229) that would authorize the Nevada Department of Health and Human Services to stop the exploitation of foreign physicians who have come to the state to provide care to residents in underserved areas, the Las Vegas Sun reports. The measure now goes to Gov. Jim Gibbons (R) for his approval (Allen, Las Vegas Sun, 5/28). A September 2007 Sun investigation of the J-1 visa program found that some foreign physicians were forced by their sponsors to work up to 100 hours per week, and were being "cheated out of their salaries" and "diverted from the patients" in underserved areas whom they were supposed to help (Kaiser Daily Health Policy Report, 8/6/08).The legislation would make violations of the J-1 program more clearly punishable under state law and prosecutable by the attorney general"s office; charge J-1 physician sponsors a fee to cover the cost of enforcing the law; and protect whistle-blowers (Las Vegas Sun, 5/28).
generic viagra online
Active Commuters Have Fewer Heart Disease Risk Factors
Men and women who walk or ride a bike to work appear more fit, and men are less likely to be overweight or obese and have healthier triglyceride levels, blood pressure and insulin levels, according to a report in the July 13 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.
News of the day
How Superbugs Control Their Lethal Weapons
It appears that some superbugs have evolved to develop the ability to manipulate the immune system to everyone"s advantage.
Cardiovascular

Eiger BioPharmaceuticals Acquires Exclusive License To Novel Hepatitis C Virus (HCV) Technology From Stanford University

Eiger BioPharmaceuticals, Inc., a biotechnology company developing antiviral therapies, announced today that it has licensed the exclusive worldwide rights to novel Hepatitis C Virus (HCV) technology from Stanford University. This technology, discovered in the lab of Stanford scientist and Eiger founder Dr. Jeffrey Glenn, M.D., Ph.D., is focused on a variety of novel targets, including key features of NS4B, a non-structural protein in the HCV genome, which binds to HCV-RNA and is required for viral replication. "We are delighted to have licensed the rights to this exciting new technology from Stanford University," said David Cory, President and CEO of Eiger. "Disrupting the interaction between NS4B and HCV-RNA may be a promising new method to treat HCV infection and help combat drug resistance to HCV polymerase and protease inhibitors. We are rapidly advancing novel small molecule inhibitors of NS4B-RNA binding into the clinic for the benefit of clinicians and HCV patients." "The unique two component nature of the NS4B-RNA target appears to decrease the virus" ability to escape inhibition by the small molecule inhibitors in development at Eiger, and that should decrease HCV resistance to this type of antiviral therapy," said Jeffrey Glenn. "These virus specific agents in development at Eiger possess the promise of more effective, oral drugs that can be essential components of all future cocktails for HCV therapy." About Hepatitis C Virus Infections from HCV have reached pandemic proportions, affecting over 150 million people worldwide. According to the Centers for Disease Control (CDC), 3.9 million Americans have been exposed to HCV, resulting in 2.7 million cases of chronic infection. Chronic HCV infection leads to serious liver disease (e.g. liver scarring and cirrhosis) and is the leading cause of liver cancer and liver transplantation in the U.S. About Eiger BioPharmaceuticals, Inc. Eiger is a biopharmaceutical company focused on the discovery and development of new antiviral agents against novel targets for the treatment of hepatitis virus infections. Eiger"s pipeline includes repurposed clinical stage therapeutic agents as well as preclinical NCEs from discovery that exhibit antiviral activity against Hepatitis C, Hepatitis D, and other viruses. Eiger BioPharmaceuticals, Inc


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009